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Abstract 
Stewart J. Anderson, PhD 
 
The Effects of Misspecification of Submodels in Joint Modeling of Repeated Measures and 
Time-to-Event Outcomes 
 
Jason M. Mao, MS 
 
University of Pittsburgh, 2019 
 
 
Abstract 
Glioblastoma (GBM) is the most common form of primary brain tumor in the US. It is 
highly aggressive and has a median survival rate of 12 to 14 months with treatment. It has 
significant effects on a patient’s neurocognitive functions, so consequently, patient reported 
outcomes (PROs) are useful for evaluating patients’ physical and mental state in a way that 
biomarkers cannot fully capture. 
Joint models, commonly used in biomedical research, combine traditional mixed models 
and survival analysis models, associating the longitudinal outcome with the time-to-event 
outcome. These models improve inferences on both types of outcomes by accounting for their 
underlying relationship, where events times are associated with the longitudinal outcomes. 
Using data from a net-clinical benefits (NCB) sub-study of RTOG 0825, which evaluated 
the effects Bevacizumab on newly diagnosed GBM patients, we fit joint models to longitudinal 
PRO measures of symptom severity and interference with daily life and time-to-event data of GBM 
progression-free survival. We use these scenarios to simulate joint models where we misspecify 
the underlying survival and longitudinal submodels to investigate the effect of model 
misspecification on the association parameter that ties together the submodels. 
We found that estimates of the association parameter are relatively robust to 
misspecification of the underlying survival distribution but not to misspecification of the assumed 
 v 
trajectory of the longitudinal submodel. Individual simulations were prone to extremely biased 
estimates, unstable estimates, and programming errors, so further investigation is suggested. 
Public Health Significance: Limited research has been done regarding the impact of 
misspecifying joint models. This thesis can inform methods to improve the analysis of biomarker 
and time-to-event data.  These models, in turn, would have a public health impact when biomarkers 
can be used as surrogates for intervention in major health related events and thus facilitate early 
intervention of those events when necessary. Here, we illustrate an example confirming a result 
from RTOG 0825 that Bevacizumab has a negative effect on PROs in addition to investigating the 
association of these PROs on GBM progression. 
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1.0 Introduction 
Glioblastoma (GBM), a type of glioma, or primary brain tumor, is the most common form 
of malignant brain tumor in the US. It currently has no known cure and has only seen small 
improvements in prognosis in recent research1. After diagnosis, the relative one-year survival rate 
of GBM patients in the US between 2000 and 2012 was 37.8% with a five-year survival rate of 
5.1%. Undiagnosed cases have a median survival rate of 3 months, but this increases up to 12 to 
14 months with diagnosis and treatment2. The current standard of care for treatment involves 
surgery followed by radio-chemotherapy. This thesis uses data from RTOG 0825, a phase III 
randomized trial of Bevacizumab among newly diagnosed GBM patients. It uses data from a net 
clinical benefits (NCB) substudy from this trial which focused on patient reported outcomes 
(PROs), including health-related quality of life and neurocognitive outcomes.  
Joint models are the analytical focus of this thesis, making use of both the longitudinal and 
survival components of the data collected in longitudinal studies to account for the underlying 
association between these two types of outcomes. This is especially useful when there is 
nonrandom, informative dropout in the data. This thesis is a simulation study that explores the 
effects of either misspecifying the functional form of the longitudinal component or the underlying 
distribution of the parametric survival submodel on the estimation of the association parameter in 
joint models. We characterize the association between symptom severity and symptom 
interference with progression-free survival in GBM patients as the clinical example to investigate 
the effect of model misspecification. 
In Section 2, we provide background on GBM and RTOG 0825, the motivating clinical 
example for this thesis. Section 3 discusses the background on joint models, the simulation of joint 
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models, and the methods used for the analysis. Section 4 describes the results of the analyses. 
Section 5 concludes this thesis with a discussion. 
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2.0 Clinical Background 
2.1 Glioblastoma 
Glioblastoma (GBM) is the most common central nervous system tumor, representing 
nearly 80% of malignant primary brain tumors as well as 27% of all primary brain tumors in the 
US. It is a highly aggressive, incurable, and deadly form of cancer, classified as a grade IV glioma 
by WHO classification, with a median survival rate of only 12 to 14 months after diagnosis2. GBM 
is divided into two subtypes: primary and secondary GBM. Primary GBMs appear without prior 
evidence of tumors and comprise the majority of GBM cases, while secondary GBMs grow from 
lower grade glioma. While there are no histological differences between the two, there are 
molecular differences that suggest the two forms develop through different pathways, so each form 
could benefit from differing prognosis and treatment2. The current standard treatment for GBM 
consists of maximal safe surgical resection, followed by concurrent radiotherapy with 
temozolomide, and then adjuvant chemotherapy with temozolomide. Surgery has shown 
improvements in prognosis for newly diagnosed patients, but the relative effectiveness of radiation 
therapy in this subgroup is more nebulous. Temozolomide is an alkylating agent that triggers 
apoptosis, or cell death, whose effectiveness has been reported to be correlated with the levels of 
methyl guanine methyl transferase (MGMT) activity. MGMT is an important DNA repair protein 
that reduces the effectiveness of alkylating chemotherapy against tumor cells3. While GBM is one 
of the most common forms of brain tumors, it is a relatively rare tumor with an age-adjusted 
incidence rate between 0.6 to 3.7 per 100,000 persons. Persons diagnosed with GBM tend to be 
older, with a median age of 64, tending to be higher for primary GBM (mean age of 55) than 
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secondary GBM (mean age of 40). It is 1.6 times more common in males than females and most 
common in white people compared to other ethnic groups including blacks, Asians, and Latinos1,2. 
Previous exposure to ionizing radiation is associated with increased risk of GBM, and certain genes 
related to allergies and the immune system are associated with decreased risk, but there is no 
significant evidence that lifestyle or environmental factors are associated with risk of GBM1. 
2.2 Radiation Treatment Oncology Group Study 0825 (RTOG 0825)  
In this thesis, we utilize a subset of data from RTOG 0825, a phase III randomized trial of 
Bevacizumab for patients with newly diagnosed Glioblastoma. RTOG 0825 was funded by the 
National Cancer Institute and conducted as a collaboration between the Radiation Therapy 
Oncology Group (RTOG), the North Central Cancer Treatment Group, and the Eastern 
Cooperative Oncology Group. Bevacizumab is a humanized monoclonal antibody that neutralizes 
vascular endothelial growth factor (VEGF), an important angiogenic factor, to inhibit tumor 
angiogenesis. It has been approved for use in treating patients with recurrent glioblastoma but, at 
the time of this study, had not been studied for its effects among patients with newly diagnosed 
GBM4. Of 978 patients enrolled into the study, 621 patients were included in the final analysis. Of 
these 621, 309 received a placebo and 312 received Bevacizumab in addition to radiotherapy and 
chemotherapy with temozolomide. The study found no significant difference in overall survival 
between the two treatment arms, with a hazard ratio of 1.13 (95% CI: 0.93-1.37). However, there 
was a significant difference in progression-free survival between the placebo (median of 7.3 
months) and Bevacizumab (10.7 months) groups (hazard ratio of 0.79; 95% CI: 0.66-0.94), but it 
is worth noting that the treatment effect varied over time. A net clinical benefits (NCB) substudy 
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showed that, over time, the Bevacizumab group had greater decreases in various of neurocognitive 
tests, including the Controlled Oral Word Association Test (p = 0.003) and the Trail Making Test, 
Part A (p = 0.04). It also found that the Bevacizumab had greater decreases in various symptom 
and health-related quality of life (QoL) outcomes such as composite symptom score (p = 0.02), 
cognitive factors (p = 0.01), treatment factors (p = 0.03), and motor dysfunction (p = 0.02)4. This 
thesis uses data from the NCB substudy. For these analyses we additionally restricted the data to 
only data from while patients are of progression-free status. 
2.3 Patient Reported Outcomes (PROs) 
Although the primary endpoints of the RTOG 0825 study were overall survival and 
progression-free survival, Patient Reported Outcomes (PROs) were analyzed in a NCB substudy 
of RTOG 0825. PROs provide important clinical information from patients’ perspectives, allowing 
us to better evaluate the costs and benefits of treatments and use information that cannot be gleaned 
from biomedical outcomes alone, or are subjective in nature, to better interpret clinical trial 
results5. There are three components to the PROs that are assessed as part of RTOG 0825. The 
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire 
and BN20 module are used to assess a patient’s QoL. It primarily evaluates patients’ physical 
function, cognitive function, and affective state. The M.D. Anderson Symptom Inventory 
(MDASI) assesses patients’ symptom severity and symptom interference with daily life, with an 
additional module assessing symptoms specifically related to brain tumors (MDASI-BT). Finally, 
neurocognitive tests, consisting of the Hopkins Verbal Learning Test-Revised, Trail Making Test 
Parts A and B, and the Controlled Oral Word Association test, were administered4. QoL can be 
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affected by both the disease itself as well as the treatment, with the effects of anti-tumor treatment 
as possibly both positive and negative. Because of GBM’s nature as a brain tumor, its effect on 
cognitive function is especially evident, with most patients experiencing cognitive deficits and 
neurocognitive decline2. A recent study has shown that using cognitive function PROs in 
conjunction with tumor prognostic variables is better than using tumor variables alone to predict 
survival and using additional endpoints besides just survival and PFS may be useful in brain cancer 
clinical trials6. Due to the aggressiveness of GBM, losing patients to follow up results in non-
ignorable missing PRO data, which we aim to use joint models in the presence of. 
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3.0 Statistical Methodology 
3.1 Overview of Joint Models 
Longitudinal studies, which are commonplace in biomedical research, are studies that 
follow individuals over a set period of time, collect repeated measurements of data, and typically 
analyze two types of outcomes: longitudinal response data and time-to-event (survival) data. Often 
cited examples are that of HIV and cancer research7,8. With HIV studies, the time to death, disease 
progression to AIDS, or data censoring (from study withdrawal, study closure, etc.) is recorded for 
each patient. In addition to baseline characteristics, repeated longitudinal measurements of 
biomarkers related to the immune system, such as CD4 lymphocyte count or viral load, are taken 
for subjects in the study. Likewise, cancer studies will record time to death or disease progression 
and measurements such as prostate specific antigen levels, for prostate cancer studies. Usually, 
research questions are constructed such that these two types of data are analyzed separately; for 
example, mixed effects models are used to analyze the longitudinal outcome and survival models 
for the time-to-event outcome, without overlap. However, in situations where the association 
between the two types of outcomes is of interest, joint models are useful7,8. If the primary focus is 
on the longitudinal outcome, in situations when dropout events are nonrandom and results in loss 
of longitudinal data, ignoring the time-to-event data can lead to biased analyses. In this situation, 
joint models allow us to produce valid inferences that account for this underlying relationship. If 
the primary focus is on the time-to-event outcome, joint models are used when we wish to analyze 
the effect of the time-dependent longitudinal measurements on the time-to-event outcome. Using 
standard survival analysis models, it is assumed that time-dependent covariables are exogeneous 
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and do not depend on the longitudinal outcome. When these covariates are endogenous and are 
related to the longitudinal outcome, such as with biomarkers and PROs, using standard survival 
analysis may lead to biased estimates. When the longitudinal covariates are dependent on the time-
to-event outcome, then joint models are required for valid inferences7. 
3.2 Joint Model Specification 
We start by defining the survival and longitudinal data we observe. We define 𝑇𝑖 as the 
true event times for each of the 𝑖 = 1, … , 𝑛 subjects and 𝐶𝑖 as the underlying potential censoring 
times for the ith subject. However, we only observe 𝑉𝑖 = 𝑚𝑖𝑛(𝑇𝑖, 𝐶𝑖) and 𝛿𝑖 = 𝐼(𝑇𝑖  ≤ 𝐶𝑖), an 
indicator of whether we observed the event or if the subject was censored. We will define 
{𝑦𝑖(𝑡), 𝑡 ≥ 0} as the full longitudinal response measured over all times 𝑡 ≥ 0. Because we do not 
observe the entire trajectory, we define 𝑦𝑖𝑗 = {𝑦𝑖(𝑡𝑖𝑗), 𝑗 = 1, … , 𝑛𝑖} as the measurements we 
observe, which we collect at each of the intermittent 𝑡𝑖𝑗 time points. We use a mixed-effects model 
to characterize the longitudinal data while incorporating subject specific intercepts and slopes 
using the following equation: 
𝑦𝑖(𝑡𝑖𝑗) = 𝑚𝑖(𝑡𝑖𝑗) + ϵij = 𝑿𝒊
𝑻(𝑡𝑖𝑗)𝜷 + 𝒁i
T(𝑡𝑖𝑗)𝒃𝑖 + 𝒖𝑖
𝑇𝜽+ 𝜖𝑖𝑗 (1) 
where mi(tij) is the true unobserved values of the longitudinal response at times tij and the error 
term 𝜖𝑖𝑗~𝑁(0, σ
2) represents measurement error, which we assume are mutually independent and 
independent of the random effects bi. We define Xi as a design matrix for the fixed effect 𝜷 and Zi 
for the random effects bi, with distributed as multivariate normal 𝒃𝑖~𝑵(𝟎, 𝚺)
7. Baseline covariates 
are represented with vector ui with a corresponding vector of regression coefficients 𝜽 to delineate 
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from the covariates we measure over time in Xi, although some authors include it within the Xi 
term8. For longitudinal outcomes that show non-linear trajectories, flexible formulations for 𝑚𝑖(𝑡) 
are preferred, using functions of time t expressed as high-order polynomials or splines. Splines are 
considered the preferred way to model highly nonlinear trajectories because they have better 
numerical properties and, due to their local nature, avoid possible problems associated with the 
global nature of polynomials7. Approaches utilizing cubic b-splines have been proposed by several 
authors9,10. For example, Brown (2005) proposes a Bayesian hierarchal model that defines 
𝑌𝑖𝑗 = ψ(𝑡𝑖𝑗) + ϵ𝑖𝑗 = ∑ β𝑖𝑘
𝑞
𝑘=1
𝐵𝑘(𝑡𝑖𝑗) + 𝑥𝑖
′α + ϵ𝑖𝑗 (2) 
where βik~𝑁(𝑏0𝑘, 𝑉0𝑘). The summation term is a random effect curve with a q-dimensional basis 
for spline functions on [0, 𝑇] and the 𝑥𝑖
′α term accounts for the effect of the baseline covariates. 
This model can also be extended to the multivariate case of longitudinal outcomes10. Another 
alternative framework uses models with the form 
𝑦𝑖(𝑡) = 𝑚𝑖(𝑡) + 𝑈𝑖(𝑡) + ϵ𝑖(𝑡) (3) 
where 𝑈𝑖(𝑡) is a mean-zero stochastic process. Possible specifications of 𝑈𝑖(𝑡) include as an 
integrated Ornstein-Uhlenbeck process or as a stationary Gaussian process, allowing trends to vary 
over time and accounting for biological fluctuation about a smooth trend8. For example, in 
Henderson (2000), the following specification is proposed: 
𝑈1𝑖(𝑡) = 𝑊1𝑖 + 𝑊2𝑖𝑡 (4) 
𝑈2𝑖(𝑡) = 𝛾1𝑊1𝑖 + 𝛾2𝑊2𝑖 + 𝛾3(𝑊1𝑖 + 𝑊2𝑖𝑡) + 𝑊3𝑖 
with the subscript i left out. In this, (𝑊1, 𝑊2) are latent zero-mean bivariate normal variables and 
𝑊3~𝑁(0, σ3
2), independent of (𝑊1, 𝑊2). The parameters γ1, γ2, and γ3 measure the association 
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between W1 and W2, while W3 is a frailty term
11. For our formulation, we will focus on 𝑚𝑖(𝑡) as a 
polynomial function of time, a simple example being 𝑚𝑖(𝑡) = (β0 + 𝑏0𝑖) + (β1 + 𝑏1𝑖)𝑡 + β2𝑡
2.  
Finally, we define the survival submodel using the relative risk formulation of the 
proportional hazards model: 
ℎ𝑖(𝑡 | 𝑀𝑖(𝑡), 𝑣𝑖) = 𝑙𝑖𝑚
𝑑𝑡→0
𝑃𝑟{𝑡 ≤ Ti < 𝑡 + 𝑑𝑡 |𝑇𝑖 ≥ 𝑡, 𝑀𝑖(𝑡), 𝑣𝑖}/𝑑𝑡 
= ℎ0(𝑡)𝑒𝑥𝑝{𝜂
𝑇𝑣𝑖 + α𝑚𝑖(𝑡)} (5) 
where 𝑀𝑖(𝑡) = {𝑚𝑖(𝑠), 0 ≤ 𝑠 < 𝑡} is the true, complete history of the unobserved longitudinal 
process up to time t. The baseline hazard function is denoted as ℎ0(⋅) and 𝑣𝑖 denotes a vector of 
baseline covariates that may or may not be the same as 𝒖𝑖
𝑇 in (1) with corresponding coefficient 
vector η. The Cox Proportional Hazards model is the most popular choice of model to use for the 
survival submodel. In it, the baseline hazard function is left unspecified and is estimated 
nonparametrically while η is estimated using a partial likelihood function. This is known as the 
semi-parametric approach7. The method this thesis focuses on is the parametric approach that 
specifies a known parametric function, such as the exponential function, for the baseline hazard 
function. The parameter 𝛼 is the measure of association between the longitudinal outcome to the 
time-to-event outcome risk. Previous studies have evaluated the potential of using the longitudinal 
outcome as a surrogate for the time-to-event outcome with the conditions that if the treatment had 
an effect on the time-to-event, the treatment had an effect on the longitudinal outcome, and vi in 
(5) includes the treatment indicator, then the risk of the event based on the longitudinal outcome 
should be independent of treatment, so 𝑚𝑖(𝑡) can serve as a surrogate
8. Alternative specifications 
for the survival submodel include the rate of change structure that uses α𝑚𝑖
′(𝑡) instead of 𝛼𝑚𝑖(𝑡) 
in (5) or the accelerated failure time framework. Though we focus on continuous longitudinal 
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outcomes in this thesis, joint models can be extended to categorical and count data within the 
generalized linear mixed model framework7. 
Initial approaches to fit joint models were based on two-stage models; in the first stage 
random effects are estimated using growth curve models, and in the second stage the estimates are 
substituted into the partial likelihood of the Cox model which is then maximized. Now, the primary 
estimation method for joint models uses maximum likelihood estimation. The likelihood function 
for the parameters of interest is  
∏ ∫[ℎ0(𝑉𝑖)𝑒𝑥𝑝{η
𝑇𝑣𝑖 + α𝑚𝑖(𝑉𝑖)}]
δ𝑖 𝑒𝑥𝑝 [− ∫ ℎ0(𝑢)𝑒𝑥𝑝{η
𝑇𝑣𝑖 + α𝑚𝑖(𝑢)}𝑑𝑢
𝑉𝑖
0
]
𝑛
𝑖=1
 
×
1
{(2πσ}2)𝑚𝑖/2
exp [− ∑
𝑌𝑖(𝑡𝑖𝑗) − 𝑚𝑖(𝑡𝑖𝑗)
2
2σ2
𝑚𝑖
𝑗=1
] 𝑝(αi|ν𝑖; 𝛿)𝑑α𝑖 (6) 
where 𝑝(αi|ν𝑖; 𝛿) is assumed multivariate normal. 
Maximization of the log-likelihood function can be done using the Expectation-
Maximization (EM) algorithm or the Newton-Raphson algorithm, though the EM algorithm is 
preferred due to some of the parameters having closed-form estimates7. 
3.3 Effects of Model Misspecification 
In this thesis we are interested in the effect model misspecification has on the estimation 
of joint model parameters. Our primary interest is in the effects of misspecifying the forms of the 
𝑚𝑖(𝑡) time polynomial and the underlying baseline hazard function ℎ0(⋅) on the association 
parameter α in the survival submodel of the joint model, a topic that has received limited attention. 
Gail (1984) shows that, in the analysis of uncensored survival data, parametric proportional 
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hazards models give unbiased estimates of treatment effects regardless of the underlying survival 
distribution. However, when censoring is present, estimates are biased. When needed covariates 
are omitted, the estimates of treatment effects are also biased, but if the exponential model is used, 
less bias is observed than if using the Cox proportional hazards model. In proportional hazards 
models, when covariates are omitted, estimates of the regression parameters are asymptotically 
biased towards zero. The degree of bias is expected to be small, unless if the true value is large12. 
Asymptotic variances from the model with omitted covariates are also smaller than those from the 
true model13. The effect of misspecifying the hazard function in parametric proportional hazards 
models will vary depending on the true underlying distribution of the survival data. In a study 
modeling against a single covariate, the size and power of hypothesis tests on the parameters of 
misspecified parametric models is generally outperformed by Cox models, with exponential 
models performing particularly poorly except in the case of no misspecification14. Kwong (2003) 
states that there is merit to fitting parametric survival models, as models are generally robust to 
misspecification if coefficients are small or if survival times are long, including in the presence of 
influential observations. However, this less true when hazard rates are rapidly increasing or 
decreasing15. Misspecifying the underlying survival distribution can also lead to models with local 
overfitting and increased bias at the lower and upper percentiles compared to at the median16,17. 
Correctly specified and asymptotically well-fitting parametric models should give efficient 
parameter estimates16, but the potential trade-off for misspecification of the underlying survival 
distribution leading to highly biased estimates is undesirable. This issue is exacerbated when there 
is a large amount of censoring present in the data14,17. As such, some authors caution against the 
use of parametric proportional hazards models due to the possibility of producing very biased 
estimates from misspecified models and misleading results for the shape and scale parameters of 
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the hazard function unless if prior knowledge suggests using a specific parametric model. They 
suggest using a Cox proportional hazards or accelerated failure time models as they are more 
robust to misspecification of the underlying survival distribution16.  
3.4 Simulation of Joint Models 
Bender (2005) provides a general framework for simulating survival data from parametric 
proportional hazards models18. First, the hazard function h(t) of proportional hazards models is 
given as 
ℎ(𝑡|𝑋) = ℎ0(𝑡)𝑒𝑥𝑝(𝑋β) (7) 
where h0(t) is the baseline hazard function of a parametric distribution, 
𝐻(𝑡|𝑋) = 𝐻0(𝑡)𝑒𝑥𝑝(𝑋β), 𝑤ℎ𝑒𝑟𝑒 𝐻0(𝑡) = ∫ ℎ0(𝑢)𝑑𝑢
𝑡
0
(8) 
describes the cumulative hazard, and the survival function, S(t), and cumulative distribution 
function, F(t), are as follows: 
𝑆(𝑡|𝑋) = 𝑒𝑥𝑝[−𝐻(𝑡)]    𝑎𝑛𝑑    𝐹(𝑡|𝑋) = 1 − 𝑒𝑥𝑝[−𝐻(𝑡)]. (9) 
Here, t represents time, X the baseline covariate vector, and β the associated regression 
coefficients. Cumulative distribution functions of variables follow a standard uniform distribution, 
denoted here as 𝑈~𝑈𝑛𝑖𝑓(0,1), and it follows that 1 − 𝑈 is also distributed as 𝑈𝑛𝑖𝑓(0,1). From 
this, letting T be the event time, we have 
𝑈 = 𝐻(𝑡|𝑋) = 𝑒𝑥𝑝[−𝐻0(𝑇) × 𝑒𝑥𝑝(𝑋β)] ~ 𝑈𝑛𝑖𝑓(0,1) (10) 
which we can then solve directly for T as long as 𝐻0(𝑡) can be inverted. So, using the following 
equation 
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𝑇 = 𝐻0
−1[−𝑙𝑜𝑔(𝑈) × 𝑒𝑥𝑝(−𝑋β)] (11) 
we only need to generate random variables from 𝑈~𝑈𝑛𝑖𝑓(0,1) in order to easily simulate survival 
data. Using the simple example of the exponential distribution, the baseline hazard function  is 
ℎ0(𝑡) = λ, giving 𝐻0(𝑡) = λ𝑡 and 𝐻0
−1(𝑡) = λ−1𝑡. Plugging this into (11) gives us 
𝑇 = λ−1[−𝑙𝑜𝑔(𝑈) × 𝑒𝑥𝑝(−𝑋β)] = −
𝑙𝑜𝑔(𝑈)
λ × 𝑒𝑥𝑝(𝑋β)
(12) 
However, when the equations become more complex, such as in the context of joint models, this 
method cannot be directly applied to simulate survival data. Crowther (2013) describes methods 
to extend Bender’s framework to cover situations such as when there is a complex baseline hazard 
function, time-dependent effects, time-varying covariates, and random effects, such as in joint 
modelling19. In these scenarios, if 𝐻0(𝑡) does not have a closed form solution or if T cannot be 
solved for analytically, numerical integration and iterative root finding methods are required to 
solve for the simulated times T. In short, if in equation (8), ℎ0(𝑡) is a complex function of t, or if 
𝑒𝑥𝑝(𝑋β) is a function of t, we must use numerical integration to calculate 𝐻(𝑡|𝑋) and then use 
iterative root finding methods to find the simulated time T that solves equation (10). 
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4.0 Results 
4.1 RTOG 0825 Data Analysis 
Our analyses use a 477 patient subset from the NCB substudy of the RTOG 0825 clinical 
trial, only collecting data from patients who had consented to participating in the NCB component 
of the study and whose tumors had not yet progressed. Among these patients, 229 (48.0%) were 
assigned to receive the placebo and 248 (52.0%) were assigned to receive the Bevacizumab 
treatment. The baseline characteristics of MGMT status and RPA class, a prognostic classification 
for GBM patients, were well balanced between the two treatment arms. These covariates are 
significantly associated with GBM prognosis, but in Gilbert (2014) were not found to have a 
significant differential effect on treatment effect or to change the treatment effect when adjusted 
for, and we will not be using them in our analyses4. In our data subset, disease progression occurred 
in 191 (83.4%) of placebo group patients and 201 (81.0%) of Bevacizumab group patients. The 
median survival time in the placebo group was 7.3 months (95% CI: 5.7 to 8.4) compared to 10.8 
months (95% CI: 10.0 to 12.4) in the Bevacizumab group, with a hazard ratio of 0.82 (95% CI: 
0.67 to 1.00, p = 0.047 by the log-rank test). When we plot the Kaplan-Meier curve (Figure 1), we 
see that early on the Bevacizumab has less progression events than the placebo group. However, 
after approximately 1.5 years the curves cross, indicating that the proportional hazards assumption 
of the hazard ratio has been violated. 
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Figure 1 Progression-Free Survival Kaplan-Meier Plot 
 
The NCB substudy in Gilbert (2014) identifies several PROs that are found to have a 
significant differential deterioration over time between the Bevacizumab and placebo treatment 
groups. PRO data is collected during assessments at 6 time points: 0, 6, 10, 22, 34, and 46 weeks 
after randomization. For our analyses, we will focus on two MDASI-BT outcome measures: the 
composite symptom score and the composite symptom interference score. These are measures of 
the symptom severity and the symptom interference with daily life, scored on a 0-10 scale with 0 
representing no severity and no interference and 10 representing extreme severity and complete 
interference. In total, 13 severity items are averaged for a composite symptom score and 6 
interference items are averaged for the composite symptom interference score (Appendix B). 
These scores are highly right-skewed, so we will use the square roots of the scores in our models 
to limit issues that may stem from modeling skewed data. As such, subsequent references to the 
symptom severity and interference scores will refer to their square roots. 
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Figure 2 Observed Longitudinal Trajectories of Symptom Severity and Interference 
 
In the plots of the symptom severity (Figure 2A) and interference (Figure 2B), the two 
groups start very close, but after about 0.25 years (3 months), the curves separate, with the 
Bevacizumab tending towards higher scores on average than the placebo group, meaning that the 
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Bevacizumab is experiencing worse symptom severity and symptom interference. Observing the 
approximately cubic shape to the symptom severity curve, we fit the following longitudinal 
submodel: 
𝑦𝑖(𝑡𝑖𝑗) = 𝑚𝑖(𝑡𝑖𝑗) + 𝜖𝑖𝑗 = (𝛽0 + 𝑏0𝑖) + (𝛽1 + 𝑏1𝑖)𝑡 + 𝛽2𝑡
2 + 𝛽3𝑡
3 + 𝛽4𝑇𝑟𝑡𝑖 + 𝛽5𝑡 ∗ 𝑇𝑟𝑡𝑖 + 𝜖𝑖𝑗(13) 
where 𝑇𝑟𝑡𝑖 is a treatment group indicator, time in the scale of years, and 
(
𝑏0𝑖
𝑏1𝑖
) ~𝑁 ([
0
0
] , [
𝜎0
2 𝜌𝜎0𝜎1
𝜌𝜎0𝜎1 𝜎1
2 ])   , ϵ𝑖𝑗~𝑁(0, σϵ
2) (14) 
which is a model with fixed quadratic and cubic powers of time, fixed treatment effect and 
treatment interaction with linear time, and random intercept and linear slope. We fit the following 
survival submodel with an exponential baseline hazard function 
ℎ𝑖(𝑡) = λ𝑒𝑥𝑝(η ∗ 𝑇𝑟𝑡𝑖 + α𝑚𝑖(𝑡)) (15) 
where 𝑚𝑖(𝑡) is from (13). For the symptom interference joint model, we fit a similar submodel 
without the cubic time term: 
𝑦𝑖(𝑡𝑖𝑗) = 𝑚𝑖(𝑡𝑖𝑗) + 𝜖𝑖𝑗 = (𝛽0 + 𝑏0𝑖) + (𝛽1 + 𝑏1𝑖)𝑡 + 𝛽2𝑡
2 + 𝛽4𝑇𝑟𝑡𝑖 + 𝛽5𝑡 ∗ 𝑇𝑟𝑡𝑖 + 𝜖𝑖𝑗 (16) 
with random effects and measurement error specified just as in (14) and the survival submodel 
specified as in (15), using the 𝑚𝑖(𝑡) from (16). Though standard survival parametric regression 
suggests that the survival distribution may be better fit as Weibull, these joint models fail to run 
with a Weibull survival submodel on our data, so we will use the exponential baseline hazard for 
our joint models. Standard mixed models of the symptom interference model also suggest 
modeling with cubic time, but joint models with the cubic term fail to converge, so we fit a 
quadratic model. Analyses are performed using the JM package in R (see Appendix A). 
Results for the symptom severity model described above is in the following Table 1 and 
symptom interference in Table 2. In both the symptom severity and interference joint models the 
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Table 1 Symptom Severity Score Joint Model Results 
Parameter Coefficient Std. Error p-value 
Longitudinal Submodel 
Intercept β0 1.0564 0.0323 <0.0001 
Time 𝛽1 1.1738 0.2166 <0.0001 
Time2 𝛽2 -3.4508 0.6201 <0.0001 
Time3 𝛽3 2.3895 0.4710 <0.0001 
Treatment 𝛽4 -0.0677 0.0425 0.1115 
Time*Treatment 𝛽5 0.2376 0.0879 0.0069 
Survival Submodel 
Treatment 𝜂 -0.0648 0.1013 0.5525 
Association 𝛼 -0.0003 0.0001 0.0029 
Log(Scale) 𝑙𝑜𝑔(𝜆) -1.2869 0.0745 <0.0001 
Random Effects Variance-Covariance 
σ0 0.3826   
σ1 0.3517   
𝜌 0.2495   
Measurement Error 
𝜎𝜖 0.3489   
 
 
Table 2 Symptom Interference Score Joint Model Results 
Parameter Coefficient Std. Error p-value 
Longitudinal Submodel 
Intercept 𝛽0 1.2451 0.0486 <0.0001 
Time 𝛽1 -0.5564 0.1289 <0.0001 
Time2 𝛽2 0.2556 0.1011 0.0115 
Treatment 𝛽3 -0.0144 0.0666 0.8284 
Time*Treatment 𝛽4 0.3710 0.1332 0.0053 
Survival Submodel 
Treatment 𝜂 -0.0461 0.1023 0.6520 
Association 𝛼 -0.0342 0.0153 0.0254 
Log(Scale) 𝑙𝑜𝑔(𝜆) -1.2299 0.0782 <0.0001 
Random Effects Variance-Covariance 
σ0 0.5834   
σ1 0.4662   
𝜌 -0.1328   
Measurement Error 
𝜎𝜖 0.5763   
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effects of time and the interaction between time and treatment were significant, but not the 
treatment main effect, in the longitudinal submodel. The interaction coefficient in both models 
indicates that the Bevacizumab group has a more quickly increasing slope in symptom scores than 
the placebo group. In the survival submodel, neither joint model found the treatment effect to be 
significantly associated with progression-free survival. Both models found a significant 
association between the longitudinal outcome and survival, with 𝛼 = -0.0003 (p = 0.003) in the 
symptom severity model and 𝛼 = -0.0342 (p = 0.025) in the symptom interference model. 
Interestingly, the models seem to indicate increased (worse) symptom scores are associated with 
a reduction in hazard rate. In the symptom severity joint model, including cubic time leads to 
rapidly increasing values of the outcome, so the association parameter is sensitive to this and is 
very small compared to in the symptom interference joint model’s association parameter. These 
results will be used to inform our simulations.  
4.2 Simulation Results 
Our first simulation is based on the symptom severity joint model, specifying the assumed 
longitudinal trajectory as in (13) and the survival submodel as in (15), using the parameter values 
of  𝛽0, 𝛽1, 𝛽2, 𝛽3, 𝛽4, 𝛽5, 𝜎0, 𝜎1, 𝜌, 𝜆, 𝜂, and 𝜎𝜖 from Table 1 to simulate data and fit joint models. 
We then misspecify the survival submodel to have a Weibull underlying distribution, using 
ℎ0(𝑡) = λ
γγ𝑡γ−1 (17) 
as the baseline hazard function. Our second is based on the symptom interference joint models, 
with (16) and (15) as the assumed longitudinal and survival model specification, using the 
parameters from Table 2. We then misspecify the longitudinal component as 
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𝑦𝑖(𝑡𝑖𝑗) = 𝑚𝑖(𝑡𝑖𝑗) + ϵ𝑖𝑗 = (β0 + 𝑏0𝑖) + (β1 + 𝑏1𝑖)𝑡 + β4𝑇𝑟𝑡𝑖 + β5𝑡 ∗ 𝑇𝑟𝑡𝑖 + ϵ𝑖𝑗 (18) 
without a quadratic time term. Longitudinal outcomes are simulated at up to 6 time points: 0, 0.2, 
0.4, 0.6, 0.8, and 1.0 years, evenly spaced and covering a similar time period as the original data. 
Treatment group membership is simulated from a Bernoulli(0.5) distribution. A 5% chance of 
random missingness in the longitudinal data is generated from a uniform 𝑈(0,1) distribution. 
Survival data is simulated as described in Section 3.3, with disease progression times and 
censoring times simulated according to the same hazard function, as we assume censoring is 
informative, selecting the minimum of the two as the observed event. Longitudinal measurements 
simulated after the observed event time are deleted as well as patients with zero longitudinal data. 
Administrative censoring is applied at 3 years. For each model, 500 simulations are generated with 
longitudinal and survival outcomes for 200 patients in each simulation (Appendix A). 
Results for the simulated symptom severity joint models are presented in Table 3, where 
we display the bias, percent bias, coverage probability (CP), and mean square error (MSE) of the 
estimates of 𝛼 from the simulations. For the correctly specified exponential baseline hazard model, 
of 500 simulations, 45 (9%) had non-positive-definite Hessian matrices and gave parameter 
estimates that cannot be used. Another 122 (24.4%) entirely failed to run, giving fatal errors, 
leaving N = 333 (66.6%) simulations to analyze. In the incorrectly specified Weibull baseline 
hazard model, 42 (9.4%) had non-positive-definite Hessian matrices and 153 (30.6%) encountered 
fatal errors, leaving N = 305 (61%) simulated models to analyze. In the longitudinal submodel, we 
note a moderate amount of bias in the time parameters of both the correctly and incorrectly 
specified models and less so in estimates of the treatment effects (Table 3). The Weibull model 
tends to be less biased but have lower coverage probability than the exponential model. In the 
survival submodel, both joint models are moderately biased in the estimate of the treatment effect 
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and extremely biased with respect to the association parameter 𝛼, though the correctly specified 
model performs slightly better. The simulated estimates of the variance-covariance matrices and 
𝜎𝜖 seem to perform well in both models. However, as seen in Figure 3A, there are extreme 
observations heavily influencing the mean of the simulated alpha parameters from both joint 
models. In Figure 3B, we see trimming the 20% of the simulations based on the alpha parameter 
 
Table 3 Misspecified Survival Submodel Simulation Results 
Parameter  Truth Bias % Bias CP MSE Bias % Bias CP MSE 
  Exponential (N = 333) Weibull (N = 305) 
Longitudinal Submodel 
Intercept β0 1.056 0.001 0.11 91.9 0.016 -0.000 -0.04 84.4 0.017 
Time 𝛽1 1.174 -0.268 -22.84 74.5 1.944 -0.250 -21.31 68.8 2.072 
Time2 𝛽2 -3.451 0.773 -22.39 72.7 16.312 0.729 -21.13 67.0 17.427 
Time3 𝛽3 2.390 -0.531 -22.24 71.8 7.700 -0.503 -21.03 66.7 8.230 
Treatment 𝛽4 -0.068 0.003 -5.04 94.0 0.008 0.003 -5.01 85.9 0.009 
Time* 
Treatment 𝛽5 
0.238 -0.005 -2.02 96.4 0.008 -0.005 -2.20 88.6 0.008 
Survival Submodel 
Treatment 𝜂 -0.065 -0.020 30.62 93.4 0.057 -0.023 35.55 85.6 0.056 
Association 𝛼 -0.0003 -0.083 31668 65.2 4.009 -0.091 34649 58.9 4.377 
Random Effects Variance-Covariance 
σ0 0.383 -0.005 -1.3  0.001 -0.005 -1.2  0.001 
σ1 0.352 -0.015 -4.3  0.005 0.017 -4.9  0.006 
𝜌 0.249 0.019 7.6  0.026 0.004 1.5  0.030 
Measurement Error 
𝜎𝜖 0.349 0.009 2.7  0.010 0.009 2.5  0.009 
 
still leaves us with a substantial right tail. In Figure 3C, trimming by 40% gives a better picture of 
the distribution of the simulated alphas near 0. We see that the simulated alphas are biased 
positively, away from the true parameter. In Table 4, when examining the median and trimmed 
means of the simulated alphas, while still moderately biased, it is significantly less biased than the 
untrimmed mean.  Here the misspecified Weibull model is less biased and generally performs 
better than the correctly specified exponential model. 
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Figure 3 Histogram of Alphas from Simulation 1 
 
Table 4 Trimmed and Median Alphas from Simulation 1 
  Truth 
(10-2) 
Bias 
(10-2) 
% Bias CP MSE 
(10-6) 
Bias 
(10-2) 
% Bias CP MSE 
(10-6) 
  Exponential Weibull 
20% Trimmed -0.026 0.140 -532.3 68.5 46.308 0.015 -58.0 71.2 0.737 
40% Trimmed 0.008 -32.5 67.2 0.010 0.006 -23.9 76.2 0.008 
Median 0.009 -34.6   0.007 -27.0   
 
Results for the simulated symptom interference joint models are presented in Table 5. 
There are significantly fewer errors in these joint models. In the correctly specified quadratic 
model, 3 (0.6%) had non-positive definite Hessian matrices and 13 (2.6%) encountered fatal errors, 
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leaving 484 (96.8%) to analyze. In the misspecified linear model, there are 4 (0.8%) with non-
positive-definite Hessian matrices and 30 (6%) that ran with fatal errors, leaving 469 (93.8%) 
simulations for analysis. Here, we see that the moderate to significant amount of bias present in 
 
Table 5 Misspecified Longitudinal Submodel Simulation Results 
Parameter  Truth Bias % Bias CP MSE Bias % Bias CP MSE 
  Quadratic (N = 484) Linear (N = 469) 
Longitudinal Submodel 
Intercept β0 1.245 -0.007 -0.6 92.6 0.006 -0.015 -1.2 91.7 0.008 
Time 𝛽1 -0.556 0.114 -20.5 58.7 0.082 0.237 -42.5 34.5 0.072 
Time2 𝛽2 0.256 -0.121 -47.4 53.3 0.076     
Treatment 𝛽3 -0.014 -0.004 25.6 94.0 0.012 0.020 -138.3 89.8 0.014 
Time* 
Treatment 𝛽4 
0.371 0.003 0.9 95.2 0.020 -0.065 -17.5 79.7 0.035 
Survival Submodel 
Treatment 𝜂 -0.046 -0.027 57.6 95.0 0.062 -0.180 390.5 81.7 0.148 
Association 𝛼 -0.034 0.042 -124.4 50.4 0.006 0.158 -463.2 44.3 0.088 
Random Effects Variance-Covariance 
σ0 0.583 -0.007 -1.2  0.002 0.003 0.6  0.027 
σ1 0.466 -0.049 -10.5  0.019 -0.149 -32.0  0.056 
𝜌 -0.136 0.020 -15.2  0.037 0.051 -38.0  0.350 
Measurement Error 
𝜎𝜖 0.576 0.002 0.400  0.000 0.008 1.4  0.001 
 
the correctly specified simulations is exacerbated in the misspecified simulation joint models for 
all parameters. We also observe that coverage probability for the time parameters is fairly low in 
the quadratic simulations and even lower in the linear simulations, although the simulated 
estimates of the treatment parameters performed relatively well. Significant bias of the association 
parameter is also present here, though not nearly to the extent in the symptom severity simulations. 
As seen in Figure 4A, like the symptom severity model simulations, there are large values of the 
simulated alphas affecting the mean bias, though not as extreme as in the previous simulations. 
Figure 4B shows the 20% trimmed histogram of alpha parameter estimates. We observe that the 
misspecified linear model has a longer right tail, though both simulations are right skewed. 
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Figure 4 Histogram of Alphas from Simulation 2 
 
Trimming the simulated alphas only offered a marginal improvement in mean bias here (Table 6), 
with the median faring better, though they are still very biased. In these symptom interference 
simulations, we can see that misspecifying the longitudinal submodel clearly causes our estimates 
of the association parameter to be biased in the positive direction. 
 
Table 6 Trimmed and Median Alphas from Simulation 2 
  Truth  Bias  % Bias CP MSE  Bias  % Bias CP MSE  
  Quadratic Linear 
20% Trimmed -0.034 0.039 -115.3 48.2 0.003 0.162 -474.9 48.6 0.041 
Median 0.019 -55.5   0.114 -333.8   
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5.0 Discussion 
In this thesis we used simulations to examine the effects of misspecifying the longitudinal 
and survival submodels in joint modeling, using scenarios based on fitting these models to PROs 
and progression-free survival data in GBM patients. Through applying joint models to the RTOG 
0825 data, we confirmed the Gilbert (2014) finding that Bevacizumab patients had a greater 
deterioration in time in symptom severity and interference scores than placebo patients. Though 
our models, which were only conducted on a subset of the RTOG 0825 patients, found that the 
treatment effect was not significantly associated with progression-free survival, we did find that 
the longitudinal symptom outcomes were significantly associated with progression-free survival, 
even if the association was very small. 
In our simulation based on symptom severity, we found that misspecifying the underlying 
survival submodel only had a minor impact on estimates of the association parameter in joint 
models. In fact, the misspecified Weibull submodel appeared to perform even better than the 
correctly specified exponential submodel, requiring further investigation. In the simulation based 
on symptom interference, where we misspecified the longitudinal trajectory, we found that fitting 
a linear trajectory to an assumed quadratic trajectory has a large impact on parameter estimation, 
especially with respect to estimates of the association parameter, where we see a tendency to 
overestimate the association parameter. However, we also note that because of the very small 
association parameters, a small amount of bias could reflect a very large percent bias. 
Many issues arose in our analysis and simulation of joint models. We only evaluated the 
exponential and Weibull underlying survival distributions, which are closely related. Other 
specifications of the survival submodel could be investigated, including using semi-parametric 
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over parametric baseline hazards or the rate of change over the current value structure. Some 
authors suggest modeling the baseline hazard function with splines, especially if there are turning 
points in the underlying hazard function, something simpler parametric models cannot capture20. 
The RTOG 0825 clinical dataset showed that the survival curves do not meet the proportional 
hazards assumption, which could be affecting the estimation and simulation of these parameters. 
Other formulations of the longitudinal submodel should be investigated. Splines have been 
suggested as a better alternative to polynomial modeling so we can reduce issues where the 
assumed longitudinal trajectory has a large rate of change as we see in our models. Our simulated 
longitudinal data would sometimes fall outside the range of the data it was based on, since the 
MDASI scores are discrete 0-10 scores, which may have influenced our simulated joint models. 
There was a higher rate of administrative censoring compared to the original data, but when we 
raised the time limit on administrative censoring, we saw an increased amount of errors in our 
simulations. This suggests that estimation of joint models can be problematic when there is a large 
gap between the period of time that longitudinal data is collected and survival events occur. 
However, this is a common feature of many datasets of this nature and could be an area of further 
research.  
5.1 Conclusion 
The results from this thesis show that joint modeling, while a useful tool for incorporating 
longitudinal and survival analysis together, can be affected by various elements of the data and 
modeling process. To this end, under our specific formulation of joint models, the estimation of 
the association parameter, alpha, our primary parameter of interest, seems to be relatively robust 
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to the misspecification of the underlying survival distribution but not of the true form of the 
longitudinal trajectory. However, this is difficult to fully evaluate when even our correctly 
specified simulations gave biased estimates of alpha and our simulated models produced a not 
insignificant number of extreme estimates of alpha. We find that joint models are effective at 
evaluating the association between longitudinal and time-to-event outcomes but would advise 
caution in choosing how to specify the submodels. Though we did not explore this aspect, 
including additional significant covariates may also improve the estimation of the parameter of 
interest. We suggest that further research into scenarios when the structure of the data is not ideal 
and could benefit from more complex submodel specifications would improve the practical 
application of joint modeling. 
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Appendix Simulation Code 
library(JM) 
library(plyr) 
library(dplyr) 
library(mvtnorm) 
 
##################################### 
###### Data Description 
 
#### Dataset 
#   mdasi: longitudinal dataset 
## Variables 
#   CN: subject identifier 
#   RXf: treatment group assignment 
#   Time_Years: time of assessment, in the scale of years 
#   SYMPTOM: symptom severity score 
#   INF: symptom interference score 
 
#### Dataset 
#   surv_m: survival dataset 
## Variables 
#   PFS: indicator of progression-free survival 
#   PFSYears: time of event or censoring, in the scale of years 
 
##################################### 
###### Analysis of RTOG 0825 data 
 
## establishing the parameteric regression model 
survExp <- survreg(Surv(PFSYears, PFS) ~ RXf, dist = "exponential", data = 
surv_m, x = TRUE) 
 
## Mixed Model: square root of symptom severity score 
lmeSym <- lme(sqrt(SYMPTOM) ~ RXf*Time_Years + I(Time_Years^2) + 
I(Time_Years^3), random = ~ Time_Years | CN, data = mdasi, na.action = 
na.omit) 
 
## Mixed Model: square root of symptom interference score 
lmeInf <- lme(sqrt(INF) ~ RXf*Time_Years + I(Time_Years^2), random = ~ 
Time_Years | CN, data = mdasi, na.action = na.omit) 
 
## Joint Model: Symptom Severity Score with Progression-free Survival, 
assuming underlying exponential surival distribution 
jointFit <- jointModel(lmeSym, survExp, timeVar = "Time_Years", method = 
"weibull-PH-aGH", scaleWB = 1) 
 
 
## Extracting parameters from the joint model to use in simulation 
fittedVCV <- jointFit$coefficients$D 
longCoef <- jointFit$coefficients$betas 
MeasureErr <- jointFit$coefficients$sigma 
survCoef <- jointFit$coefficients$gammas[-1] 
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assocParm <- jointFit$coefficients$alpha 
weibScale <- exp(jointFit$coefficients$gammas[1]) 
weibShape <- 1/jointFit$coefficients$sigma.t 
 
 
##################################### 
###### Simulation Code: using symptom severity joint model as the basis 
 
# Setting number of simulations 
NSim <- 500; 
 
# Creating empty lists to store the simulated data and joint models 
ModelStorage <- vector("list", NSim) 
DataStorage <- vector("list", NSim) 
SurvStorage <- vector("list", NSim) 
convcodes <- rep(NA, NSim); 
 
for(SimCount in 1:NSim) 
{ 
  ## Simulating random intercept and slopes for N people 
  Nsub <- 200; 
   
  ######################################################## 
  ### Simulating longitudinal data 
  NGroup <- 2; # establishing number of treatment groups 
  poly <- 3; # setting order of polynomial time 
   
  ## Specifying true fixed parameters, using parameters extracted above 
  b0 <- longCoef[1]; 
  bTime <- longCoef[3:5]; # Set population time polynomial parameters 
  bGroup <- longCoef[c(2,6)]; # Main Effect and interaction 
 
  ## creating the vector of time points for which we simulate data 
  tt <- seq(0, 1, by = 0.2) 
  Nobs <- length(tt) 
   
  timepolytemp <- matrix(rep(NA, Nobs*poly), nrow = poly, ncol = Nobs) 
  for(i in 1:poly) 
  { 
    timepolytemp[i,] <- tt^i; 
  } 
  zeroplaceholder <- matrix(rep(0, Nobs*poly), nrow = poly, ncol = Nobs) 
   
  timepoly <- rbind(timepolytemp, zeroplaceholder) 
   
  ## Randomly generating group assignment 
  Group <- as.matrix(sample(c(0,1), Nsub, replace = TRUE), ncol = 1) 
   
  ## Specifying and simulating from a multivariate normal distribution 
  vcv <- matrix(as.numeric(fittedVCV), nrow = 2) 
   
  mu <- matrix(rep(0,2),ncol = 1) 
  U <- as.matrix(rmvnorm(Nsub, mean = mu, sigma = vcv), ncol = 2) 
   
  # Create subject-wise coefficients 
  beta0<-b0+U[,1] 
  beta1<-bTime[1]+U[,2] 
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  beta2<-bTime[2] 
  beta3<-bTime[3] 
  betaGroup <- bGroup[1] 
  betaGroupTime <- bGroup[2] 
   
  s1 <- MeasureErr; # standard deviation of measurement error 
  tempE <- rnorm(Nsub*Nobs, mean = 0, sd = s1)  
  Eij <- matrix(tempE, nrow = Nsub, byrow = TRUE) # matrix of measurement 
error 
   
  # Calculating and constructing the matrix of simulated longitudinal 
outcomes 
  Y<-matrix(rep(NA,Nsub*Nobs),nrow=Nsub) 
  for (i in 1:Nsub) { 
    for (j in 1:Nobs) { 
      Y[i,j] <- (  
beta0[i]+beta1[i]*timepoly[1,j]+beta2*timepoly[2,j]+beta3*timepoly[3,j] + 
                    betaGroup*Group[i] + 
(betaGroupTime*Group[i]*timepoly[1,j]) + Eij[i,j] ) 
    } 
  } 
   
  ## Adding random censoring 
  rcens <- matrix(runif(Nsub*Nobs),nrow=Nsub) 
  Y[which(rcens<=0.05)] <- NA 
   
   
  ######################################################## 
  ### Simulating Survival Data  (see section 3.3) 
   
  # Setting parameters based on joint model of real data 
  alpha <- assocParm 
  Hscale <- weibScale # lambda 
  Hshape <- weibShape  # gamma, = 1 if exponential 
  ZGroup <- survCoef[1] 
   
  # Generating U from uniform distribution 
  UVec <- runif(Nsub*2); 
  UMat <- matrix(UVec, ncol = 2) 
  logU <- -log(UMat) 
   
  # Creating empty dataframe to hold simulated survival dataset 
  tempEventData <- as.data.frame(matrix(rep(NA, Nsub*4), ncol = 4)) 
  names(tempEventData) <- c("TrueEventTime", "TrueCensTime", "ObsTime", 
"ObsEvent") 
   
  # Numerical integration and approximation to solve for T that optimizes 
equation (10) from section 3.3 
  #  Simulates true survival and censoring times 
  for(i in 1:Nsub){ 
    testfunc <- function(t) 
    { 
      (t^(Hshape-1))*Hshape*Hscale*exp(ZGroup*Group[i])* 
        exp(alpha*(beta0[i] + beta1[i]*t + beta2*t^2 + beta3*t^3 + 
betaGroup*Group[i] + betaGroupTime*t*Group[i])) 
    } 
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    Tvec <- seq(0.001, 3.05, by = 0.001) 
    NumInt <- rmutil::int(testfunc, a = 0, b = Tvec) 
    tempEventData$TrueEventTime[i] <- Tvec[which.min(abs(NumInt - 
logU[i,1]))] 
    tempEventData$TrueCensTime[i] <- Tvec[which.min(abs(NumInt - logU[i,2]))] 
 
  } 
   
  # Using T_i and C_i to find V_i and delta_i 
  tempEventData$ObsTime <- apply(tempEventData[,1:2], 1, FUN = min) 
  tempEventData$ObsEvent <- as.numeric(tempEventData[,3] == 
tempEventData[,1]) 
   
    SurvData <- tempEventData[,3:4] 
  names(SurvData) <- c("SurvTime", "Event") 
   
  # Set administrative censoring and random censoring 
  MaxTime <- 3 # Administrative censoring + reigning in very high survival 
times 
  SurvData$Marker <- 0 
  SurvData$Marker[which(SurvData[,1] > MaxTime)] <- 1 
  SurvData$SurvTime[which(SurvData$Marker == 1)] <- MaxTime 
  SurvData$Event[which(SurvData$Marker == 1)] <- 0 
  SurvData <- SurvData[,-3] 
   
   
  ######################################################## 
  ### Data Cleanup, consolidating into readable simulated longitudinal and 
survival datasets 
   
  # Subject IDs 
  id <- seq(1, Nsub, 1) 
   
  Y_wide <- as.data.frame(cbind(id, Y)) 
  Y_long <- reshape(Y_wide, direction = "long", varying = 
list(names(Y_wide)[2:(Nobs+1)]), 
                    v.names = "Y", idvar = "id", timevar = "Time", times = 
tt) 
  row.names(Y_wide) <- c(1:nrow(Y_wide)) 
   
  Y_long <- Y_long[order(Y_long$id, Y_long$Time),] 
  row.names(Y_long) <- c(1:nrow(Y_long)) 
   
  SurvDataFull <- as.data.frame(cbind(id, Group, SurvData)) 
   
  tempJoint <- merge(SurvDataFull, Y_long, by = "id") 
   
  JointData <- tempJoint[-which(tempJoint$Time > tempJoint$SurvTime),] 
  JointData <- JointData[-which(is.na(JointData$Y)),] ## removing NAs to 
avoid errors 
   
  DataStorage[[SimCount]] <- JointData 
   
  SurvFinal <- aggregate(JointData[,-1], by = list(id=JointData$id),head,1) 
  SurvStorage[[SimCount]] <- SurvFinal 
   
  #### Dataset Description 
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  ## Variables 
  #   id: subject identifier 
  #   Group: treatment group assignment 
  #   Time: time of longitudinal assessment, in the scale of years 
  #   Y: simulated longitudinal outcome 
  #   Event: indicator of event or censoring 
  #   SurvTime: time of event or censoring, in the scale of years 
   
  ######################################################## 
  ### Joint Models 
   
  myLME <- NULL; mySurv <- NULL; myJM <- NULL; # safety measure to ensure old 
models aren't reused if a component fails 
   
  # Code to continue running when running into an error 
  tryCatch({ 
    # Mixed model 
    myLME <- lme(Y ~ factor(Group)*Time + I(Time^2) + I(Time^3), random = ~ 
Time | id, data = JointData, na.action = na.omit) 
    # Survival Model 
    mySurv <- survreg(Surv(SurvTime, Event) ~ factor(Group), dist = 
"exponential", data = SurvFinal, x = TRUE) 
    # Joint Model 
    myJM <- jointModel(myLME, mySurv, timeVar = "Time", method = "weibull-PH-
aGH", scaleWB = 1) 
   
    # Saving joint model output 
    ModelStorage[[SimCount]] <- myJM 
  }, error = function(e){paste("Error"); ModelStorage[[SimCount]] <- NA}) 
   
} 
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